#22: Novo Nordisk's next gen weight loss drug

Novo Nordisk, known for its obesity drugs Ozempic and Wegovy, reported strong profit and revenue for 2024, surpassing Wall Street expectations. However, the company expects slower sales growth in 2025 due to rising competition, particularly from Eli Lilly, and pricing pressures. Despite this, Novo Nordisk remains optimistic, citing continued strong demand for obesity treatments and its drug pipeline, including CagriSema and amycretin. The company’s stock experienced volatility, partly due to concerns about obesity drug demand and geopolitical factors like tariffs. While uncertain about global trade impacts, Novo Nordisk is confident in the long-term potential of its drugs. Hosted on Acast. See acast.com/privacy for more information.